Live from the NIH registry
Studies recruiting near Modesto right now
Top 25 of 111 recruiting studies, sorted by proximity — each links to its official registry page
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Phase 3
Interventional 1,273 participants sought
Kaiser Permanente-Modesto — Modesto, California (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: NRG Oncology
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2, Phase 3
Interventional 131 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of BLB-201 RSV Vaccine in Infants and Children
Respiratory Syncytial Virus Infections
Phase 1, Phase 2
Interventional 137 participants sought
Paradigm Clinical Research - Modesto — Modesto, California (0.3 mi)
· Sponsor: Blue Lake Biotechnology Inc.
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Breast Neoplasms, Carcinoma, Ductal, Breast
N/A
Interventional 725 participants sought
Stockton Hematology Oncology Medical Group — Stockton, California (27.1 mi)
· Sponsor: Natera, Inc.
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Saint Joseph's Medical Center — Stockton, California (27.1 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Phase 2
Interventional 156 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Obesity, Heart Failure
Phase 3
Interventional 5,610 participants sought
St. Joseph's Medical Center — Stockton, California (27.1 mi)
· Sponsor: Novo Nordisk A/S
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1
Phase 3
Interventional 150 participants sought
Paradigm Clinical Research - Modesto — Modesto, California (0.3 mi)
· Sponsor: vTv Therapeutics
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration, nAMD
Phase 3
Interventional 304 participants sought
Retinal Consultants Medical Group, Inc - Modesto (RCA) — Modesto, California (0.3 mi)
· Sponsor: Amgen
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 626 participants sought
Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B) — Stockton, California (27.1 mi)
· Sponsor: Mirati Therapeutics Inc.
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Getinge's Beating Heart Product Family Post-Market Clinical Follow-up (PMCF) Study
Off Pump Coronary Artery Bypass Surgery
N/A
Observational 200 participants sought
St. Joseph's Medical Center Stockton — Stockton, California (27.1 mi)
· Sponsor: Maquet Cardiovascular
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3
Interventional 1,500 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: NRG Oncology
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Obesity, Overweight
Phase 3
Interventional 3,600 participants sought
ACCOMPLISH-1 Research Site — Modesto, California (0.3 mi)
· Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Phase 3
Interventional 830 participants sought
Saint Joseph's Medical Center — Stockton, California (27.1 mi)
· Sponsor: Canadian Cancer Trials Group
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)